Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD) and ENDRA Life Sciences (NDRA) with bullish sentiments.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gilead Sciences (GILD)
In a report released today, Daina Graybosch from Leerink Partners maintained a Buy rating on Gilead Sciences, with a price target of $129.00. The company’s shares closed last Tuesday at $138.68.
According to TipRanks.com, Graybosch has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Gilead Sciences is a Strong Buy with an average price target of $158.05, representing a 13.7% upside. In a report issued on March 24, Scotiabank also maintained a Buy rating on the stock with a $177.00 price target.
See the top stocks recommended by analysts >>
ENDRA Life Sciences (NDRA)
In a report issued on April 5, Edward Woo from Ascendiant maintained a Buy rating on ENDRA Life Sciences, with a price target of $27.00. The company’s shares closed last Tuesday at $4.76, close to its 52-week low of $3.15.
According to TipRanks.com, Woo has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on ENDRA Life Sciences is a Moderate Buy with an average price target of $27.00.
Read More on GILD:
Disclaimer & DisclosureReport an Issue
- Leerink sees Gilead’s $5B Tubulis buy as ‘more than an oncology bolt-on’
- Gilead price target raised to $123 from $118 at RBC Capital
- Gilead to acquire Tubulis for $3.15B upfront, up to $1.85B in milestone payments
- Compugen initiated with a Buy at Lake Street
- Assembly Biosciences price target raised to $43 from $39 at Guggenheim
